China’s volume-based procurement system is facing a range of challenges, including clinical efficiency, supply chain stability, and patient access to innovative medical treatments.
Recent central government policies signal a stronger acknowledgement of these problems.
While commercial health insurance could mitigate some of these challenges, its impact remains uncertain due to restricted coverage and financial limitations.